Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b Study of Lanadelumab in Hereditary Angioedema
NCT02093923Phase 1Completed
- Sponsor
- Takeda
- Start
- May 2014
- Primary completion
- May 2015
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of lanadelumab in hereditary angioedema (HAE) (5 arms), sponsored by Takeda. Primary endpoint: Number of Participants With Serious Adverse Events and Treatment-Emergent Adverse Events. Started May 2014; status: completed.
02
Drugs
lanadelumab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT02093923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02093923.